590 related articles for article (PubMed ID: 1666046)
1. Effects of intracerebroventricular beta-funaltrexamine on mu and delta opioid receptors in the rat: dichotomy between binding and antinociception.
Liu-Chen LY; Li SX; Wheeler-Aceto H; Cowan A
Eur J Pharmacol; 1991 Oct; 203(2):195-202. PubMed ID: 1666046
[TBL] [Abstract][Full Text] [Related]
2. Effect of intracerebroventricular beta-funaltrexamine on mu opioid receptors in the rat brain: consideration of binding condition.
Liu-Chen LY; Yang HH; Li S; Adams JU
J Pharmacol Exp Ther; 1995 Jun; 273(3):1047-56. PubMed ID: 7791074
[TBL] [Abstract][Full Text] [Related]
3. Opioid delta-receptor involvement in supraspinal and spinal antinociception in mice.
Heyman JS; Mulvaney SA; Mosberg HI; Porreca F
Brain Res; 1987 Sep; 420(1):100-8. PubMed ID: 2823970
[TBL] [Abstract][Full Text] [Related]
4. Autoradiographic study of irreversible binding of [3H]beta-funaltrexamine to opioid receptors in the rat forebrain: comparison with mu and delta receptor distribution.
Liu-Chen LY; Li SX; Lewis ME
Brain Res; 1991 Mar; 544(2):235-42. PubMed ID: 1645609
[TBL] [Abstract][Full Text] [Related]
5. Interaction of beta-funaltrexamine with [3H]cycloFOXY binding in rat brain: further evidence that beta-FNA alkylates the opioid receptor complex.
Rothman RB; Bykov V; Mahboubi A; Long JB; Jiang Q; Porreca F; de Costa BR; Jacobson AE; Rice KC; Holaday JW
Synapse; 1991 Jun; 8(2):86-99. PubMed ID: 1652797
[TBL] [Abstract][Full Text] [Related]
6. Selective antagonism by naltrindole of the antinociceptive effects of the delta opioid agonist cyclic[D-penicillamine2-D-penicillamine5]enkephalin in the rat.
Drower EJ; Stapelfeld A; Rafferty MF; de Costa BR; Rice KC; Hammond DL
J Pharmacol Exp Ther; 1991 Nov; 259(2):725-31. PubMed ID: 1658309
[TBL] [Abstract][Full Text] [Related]
7. Evaluation of delta receptor mediation of supraspinal opioid analgesia by in vivo protection against the beta-funaltrexamine antagonist effect.
Sánchez-Blázquez P; Garzón J
Eur J Pharmacol; 1989 Jan; 159(1):9-23. PubMed ID: 2565240
[TBL] [Abstract][Full Text] [Related]
8. Modulation of mu-mediated antinociception by delta agonists: characterization with antagonists.
Heyman JS; Jiang Q; Rothman RB; Mosberg HI; Porreca F
Eur J Pharmacol; 1989 Oct; 169(1):43-52. PubMed ID: 2557223
[TBL] [Abstract][Full Text] [Related]
9. Chronic administration of morphine and naltrexone up-regulate mu-opioid binding sites labeled by [3H][D-Ala2,MePhe4,Gly-ol5]enkephalin: further evidence for two mu-binding sites.
Rothman RB; Bykov V; Long JB; Brady LS; Jacobson AE; Rice KC; Holaday JW
Eur J Pharmacol; 1989 Jan; 160(1):71-82. PubMed ID: 2540993
[TBL] [Abstract][Full Text] [Related]
10. Delta but not mu-opioid receptors in the spinal cord are involved in antinociception induced by beta-endorphin given intracerebroventricularly in mice.
Suh HH; Tseng LF
J Pharmacol Exp Ther; 1990 Jun; 253(3):981-6. PubMed ID: 2162954
[TBL] [Abstract][Full Text] [Related]
11. Delta receptor involvement in morphine suppression of noxiously evoked activity of spinal WDR neurons in cats.
Omote K; Kitahata LM; Nakatani K; Collins JG
Brain Res; 1991 Jul; 554(1-2):299-303. PubMed ID: 1657291
[TBL] [Abstract][Full Text] [Related]
12. Effects of intracerebroventricular administration of beta-funaltrexamine on [3H]DAMGO binding to rat brain sections.
Martin TJ; Dworkin SI; Smith JE
J Pharmacol Exp Ther; 1993 Oct; 267(1):506-14. PubMed ID: 8229781
[TBL] [Abstract][Full Text] [Related]
13. Differential antagonism of opioid delta antinociception by [D-Ala2,Leu5,Cys6]enkephalin and naltrindole 5'-isothiocyanate: evidence for delta receptor subtypes.
Jiang Q; Takemori AE; Sultana M; Portoghese PS; Bowen WD; Mosberg HI; Porreca F
J Pharmacol Exp Ther; 1991 Jun; 257(3):1069-75. PubMed ID: 1646319
[TBL] [Abstract][Full Text] [Related]
14. Pretreatment of rats with the irreversible mu-receptor antagonist, beta-FNA, fails to prevent naltrexone-induced upregulation of mu-opioid receptors.
Rothman RB; Long JB; Bykov V; Jacobson AE; Rice KC; Holaday JW
Neuropharmacology; 1990 Sep; 29(9):805-10. PubMed ID: 1963479
[TBL] [Abstract][Full Text] [Related]
15. Reversible and irreversible binding of beta-funaltrexamine to mu, delta and kappa opioid receptors in guinea pig brain membranes.
Tam SW; Liu-Chen LY
J Pharmacol Exp Ther; 1986 Nov; 239(2):351-7. PubMed ID: 3021954
[TBL] [Abstract][Full Text] [Related]
16. beta-FNA binds irreversibly to the opiate receptor complex: in vivo and in vitro evidence.
Rothman RB; Long JB; Bykov V; Jacobson AE; Rice KC; Holaday JW
J Pharmacol Exp Ther; 1988 Nov; 247(2):405-16. PubMed ID: 2846819
[TBL] [Abstract][Full Text] [Related]
17. Characteristics of dose-dependent antagonism by beta-funaltrexamine of the antinociceptive effects of intrathecal mu agonists.
Mjanger E; Yaksh TL
J Pharmacol Exp Ther; 1991 Aug; 258(2):544-50. PubMed ID: 1650833
[TBL] [Abstract][Full Text] [Related]
18. Modification by cholecystokinin octapeptide of the binding of mu-, delta-, and kappa-opioid receptors.
Wang XJ; Han JS
J Neurochem; 1990 Oct; 55(4):1379-82. PubMed ID: 2168937
[TBL] [Abstract][Full Text] [Related]
19. Chronic effect of [D-Pen2,D-Pen5]enkephalin on rat brain opioid receptors.
Tao PL; Tsai CL; Chang LR; Loh HH
Eur J Pharmacol; 1991 Aug; 201(2-3):209-14. PubMed ID: 1665782
[TBL] [Abstract][Full Text] [Related]
20. Behavioral effects of opioid peptides selective for mu or delta receptors. I. Morphine-like discriminative stimulus effects.
Locke KW; Holtzman SG
J Pharmacol Exp Ther; 1986 Sep; 238(3):990-6. PubMed ID: 3018230
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
